NVCN - Neovasc Inc.

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
0.0267
+0.0020 (+8.10%)
As of 2:20PM EDT. Market open.
Stock chart is not supported by your current browser
Previous Close0.0247
Open0.0242
Bid0.0263 x 1100
Ask0.0264 x 1000
Day's Range0.0240 - 0.0275
52 Week Range0.0200 - 1.8900
Volume14,921,797
Avg. Volume18,384,225
Market Cap49.271M
Beta2.26
PE Ratio (TTM)N/A
EPS (TTM)-0.1650
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est1.88
Trade prices are not sourced from all markets
  • PR Newswire4 hours ago

    Neovasc Announces 100th Patient to Receive Reducer Therapy in Germany

    VANCOUVER, Sept. 19, 2018 /PRNewswire/ - Neovasc, Inc. ("Neovasc" or the "Company") (NVCN) (NVCN.TO), a leader in the development of minimally invasive transcatheter mitral valve replacement technologies and in the development of minimally invasive devices for the treatment of refractory angina, announced today that a Neovasc Reducer™ (the "Reducer") has now been implanted in 100 patients in Germany. The Reducer is a wire mesh implanted into a vein in the heart which treats patients with refractory angina. A growing number of patients suffer from significant angina despite optimal medication and prior revascularisations (via percutaneous coronary intervention or coronary artery bypass graft), or when revascularization is not feasible or when the risks is too great.

  • CNW Group4 hours ago

    Neovasc Announces 100th Patient to Receive Reducer Therapy in Germany

    VANCOUVER , Sept. 19, 2018 /CNW/ - Neovasc, Inc. ("Neovasc" or the "Company") (NVCN) (NVCN.TO), a leader in the development of minimally invasive transcatheter mitral valve replacement technologies and in the development of minimally invasive devices for the treatment of refractory angina, announced today that a Neovasc Reducer™ (the "Reducer") has now been implanted in 100 patients in Germany . The Reducer is a wire mesh implanted into a vein in the heart which treats patients with refractory angina. A growing number of patients suffer from significant angina despite optimal medication and prior revascularisations (via percutaneous coronary intervention or coronary artery bypass graft), or when revascularization is not feasible or when the risks is too great.

  • PR Newswire20 hours ago

    Neovasc Announces Effective Date of Share Consolidation

    NASDAQ, TSX: NVCN VANCOUVER , Sept. 18, 2018 /PRNewswire/ - Neovasc Inc. (" Neovasc " or the " Company ") (NASDAQ: NVCN)(TSX: NVCN), a leader in the development of minimally invasive ...

  • CNW Group20 hours ago

    Neovasc Announces Effective Date of Share Consolidation

    Neovasc Announces Effective Date of Share Consolidation

  • PR Newswire7 days ago

    Neovasc Announces Amendments to Outstanding Convertible Notes, including 1-Year Extension of Note Maturity Date

    VANCOUVER, Sept. 12, 2018 /PRNewswire/ - Neovasc Inc. ("Neovasc" or the "Company") (NVCN)(NVCN.TO), a leader in the development of minimally invasive transcatheter mitral valve replacement technologies and in the development of minimally invasive devices for the treatment of refractory angina, announced today that the holders ("Holders") of its senior secured convertible notes (the "Notes") have agreed to amend certain terms of the Notes and other concessions, including a one-year extension of the maturity of the Notes from May 17, 2019 until May 17, 2020. Most importantly, the extension of the expiration date for the convertible debt by one year will provide the Company with greater flexibility for repayment of the debt, and while no predictions can be made as to conversions, this extension may ease the pressure on the conversions," commented Fred Colen, Neovasc's President and Chief Executive Officer.

  • CNW Group7 days ago

    Neovasc Announces Amendments to Outstanding Convertible Notes, including 1-Year Extension of Note Maturity Date

    VANCOUVER , Sept. 12, 2018 /CNW/ - Neovasc Inc. ("Neovasc" or the "Company") (NVCN)(NVCN.TO), a leader in the development of minimally invasive transcatheter mitral valve replacement technologies and in the development of minimally invasive devices for the treatment of refractory angina, announced today that the holders ("Holders") of its senior secured convertible notes (the "Notes") have agreed to amend certain terms of the Notes and other concessions, including a one-year extension of the maturity of the Notes from May 17, 2019 until May 17, 2020 . Most importantly, the extension of the expiration date for the convertible debt by one year will provide the Company with greater flexibility for repayment of the debt, and while no predictions can be made as to conversions, this extension may ease the pressure on the conversions," commented Fred Colen , Neovasc's President and Chief Executive Officer.

  • PR Newswire8 days ago

    Neovasc Announces Extension to Regain Compliance with Nasdaq Minimum Bid Price Rule

    VANCOUVER, Sept. 11, 2018 /PRNewswire/ - Neovasc Inc. ("Neovasc" or the "Company") (NVCN)(NVCN.TO), a leader in the development of minimally invasive transcatheter mitral valve replacement technologies and in the development of minimally invasive devices for the treatment of refractory angina, announced today (1) that it has received the decision of the Nasdaq Hearings Panel (the "Panel") to grant it a extension until October 15, 2018 to regain compliance with the US$1.00 minimum bid price requirement and (2) the Company's plans to execute the reverse stock split (share consolidation), approved at its Annual General and Special Meeting of Shareholders on June 4, 2018. The Nasdaq Stock Market LLC ("Nasdaq") held an oral hearing on August 30, 2018, at which the Panel considered Neovasc's appeal of the Nasdaq Listing Qualifications Staff (the "Staff") decision to delist the Company's common shares (the "Common Shares") from the Nasdaq Capital Market for non-compliance with the US$1.00 minimum bid price requirement.

  • CNW Group8 days ago

    Neovasc Announces Extension to Regain Compliance with Nasdaq Minimum Bid Price Rule

    VANCOUVER , Sept. 11, 2018 /CNW/ - Neovasc Inc. ("Neovasc" or the "Company") (NVCN)(NVCN.TO), a leader in the development of minimally invasive transcatheter mitral valve replacement technologies and in the development of minimally invasive devices for the treatment of refractory angina, announced today (1) that it has received the decision of the Nasdaq Hearings Panel (the "Panel") to grant it a extension until October 15, 2018 to regain compliance with the US$1.00 minimum bid price requirement and (2) the Company's plans to execute the reverse stock split (share consolidation), approved at its Annual General and Special Meeting of Shareholders on June 4, 2018 . The Nasdaq Stock Market LLC ("Nasdaq") held an oral hearing on August 30, 2018 , at which the Panel considered Neovasc's appeal of the Nasdaq Listing Qualifications Staff (the "Staff") decision to delist the Company's common shares (the "Common Shares") from the Nasdaq Capital Market for non-compliance with the US$1.00 minimum bid price requirement.

  • CNW Group8 days ago

    Neovasc Provides Initial Comments on Lawsuit

    VANCOUVER , Sept. 11, 2018 /CNW/ - Neovasc Inc. ("Neovasc" or the "Company") (NVCN)(NVCN.TO), a leader in the development of minimally invasive transcatheter mitral valve replacement technologies and in the development of minimally invasive devices for the treatment of refractory angina, has been made aware of a lawsuit filed by Endovalve Inc. and Micro Interventional Devices, Inc. (the "Plaintiffs") in the U.S. District Court for the District of New Jersey including certain allegations relating to Neovasc's transcatheter mitral valve technology, including the Tiara™ ("Tiara") device. Neovasc is a specialty medical device company that develops, manufactures and markets products for the rapidly growing cardiovascular marketplace. This news release contains forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995 and applicable Canadian securities laws regarding the Company's plans and expectations concerning the lawsuit filed against the Company, the Company's intention to defend itself vigorously, and the growing cardiovascular marketplace.

  • PR Newswire8 days ago

    Neovasc Provides Initial Comments on Lawsuit

    VANCOUVER, Sept. 11, 2018 /PRNewswire/ - Neovasc Inc. ("Neovasc" or the "Company") (NVCN)(NVCN.TO), a leader in the development of minimally invasive transcatheter mitral valve replacement technologies and in the development of minimally invasive devices for the treatment of refractory angina, has been made aware of a lawsuit filed by Endovalve Inc. and Micro Interventional Devices, Inc. (the "Plaintiffs") in the U.S. District Court for the District of New Jersey including certain allegations relating to Neovasc's transcatheter mitral valve technology, including the Tiara™ ("Tiara") device.

  • Associated Presslast month

    Neovasc: 2Q Earnings Snapshot

    The Richmond, British Columbia-based company said it had a loss of 4 cents per share. Earnings, adjusted for non-recurring costs and amortization costs, were less than 1 cent on a per-share basis. The ...

  • PR Newswirelast month

    Neovasc Announces Second Quarter 2018 Financial Results

    NASDAQ, TSX: NVCN First implant of a Neovasc Reducer™ in a U.S. patient Reducer Q2, 2018 revenue up 64% over Q2, 2017 and at 108% of Q2, 2018 plan Tiara™ featured in live case at 11th Annual TVT conference ...

  • CNW Grouplast month

    Neovasc Announces Second Quarter 2018 Financial Results

    Neovasc Announces Second Quarter 2018 Financial Results

  • What Does Neovasc Inc’s (TSE:NVCN) Ownership Structure Look Like?
    Simply Wall St.last month

    What Does Neovasc Inc’s (TSE:NVCN) Ownership Structure Look Like?

    In this article, I’m going to take a look at Neovasc Inc’s (TSE:NVCN) latest ownership structure, a non-fundamental factor which is important, but remains a less discussed subject among investors.Read More...

  • ACCESSWIRElast month

    Neovasc Inc. to Host Earnings Call

    NEW YORK, NY / ACCESSWIRE / August 8, 2018 / Neovasc Inc. (NASDAQ: NVCN ) will be discussing their earnings results in their Q2 Earnings Call to be held on August 8, 2018 at 4:30:00 PM Eastern Time. To ...

  • PR Newswirelast month

    Neovasc Announces Updated Presentation Time at the 38th Annual Canaccord Genuity Growth Conference

    NASDAQ, TSX: NVCN VANCOUVER , Aug. 8, 2018 /PRNewswire/ - Neovasc, Inc. ("Neovasc" or the "Company") (NASDAQ:NVCN)(TSX: NVCN), a leader in the development of minimally invasive transcatheter ...

  • CNW Grouplast month

    Neovasc Announces Updated Presentation Time at the 38th Annual Canaccord Genuity Growth Conference

    Neovasc Announces Updated Presentation Time at the 38th Annual Canaccord Genuity Growth Conference

  • ACCESSWIRElast month

    Biotechnology Stocks Trending on New Developments 2018

    CORAL GABLES, FL / ACCESSWIRE / August 6, 2018 / Earnings season continues to roll on this week as a number of companies report second quarter results. In fact over the last 3 months, the Health Care Select Sector SPDR Fund (XLV) has been climbing back toward its 52 week high. Likewise, both the SPDR S&P Biotech ETF (XBI) and the iShares NASDAQ Biotechnology Index ETF (IBB) have maintained their 2018 uptrend despite periodic consolidation throughout the year.

  • PR Newswirelast month

    Neovasc Announces Publication of Safety and Efficacy Results from REDUCE Study in International Journal of Cardiology

    VANCOUVER, Aug. 6, 2018 /PRNewswire/ - Neovasc Inc. ("Neovasc" or the "Company") (NVCN) (NVCN.TO), a leader in the development of minimally invasive transcatheter mitral valve replacement technologies, today announced publication of the manuscript, "Safety and efficacy of the Reducer: A multicenter clinical registry - REDUCE study" in the International Journal of Cardiology, which is available online at: https://doi.org/10.1016/j.ijcard.2018.06.116. In this published study, the safety and effectiveness of the Neovasc Reducer™ ("Reducer"), a CE-Marked medical device designed for the treatment of refractory angina, was evaluated using a real-world cohort of 141 patients in three high-volume medical centers in Milan, Tel Aviv and Antwerp. The researchers aimed to evaluate the efficacy of the Reducer in improving quality of life and reducing symptoms of angina pectoris in 141 consecutive patients suffering from coronary artery disease and chronic refractory angina.

  • CNW Grouplast month

    Neovasc Announces Publication of Safety and Efficacy Results from REDUCE Study in International Journal of Cardiology

    VANCOUVER , Aug. 6, 2018 /CNW/ - Neovasc Inc. ("Neovasc" or the "Company") (NVCN) (NVCN.TO), a leader in the development of minimally invasive transcatheter mitral valve replacement technologies, today announced publication of the manuscript, "Safety and efficacy of the Reducer: A multicenter clinical registry - REDUCE study" in the International Journal of Cardiology, which is available online at: https://doi.org/10.1016/j.ijcard.2018.06.116. In this published study, the safety and effectiveness of the Neovasc Reducer™ ("Reducer"), a CE-Marked medical device designed for the treatment of refractory angina, was evaluated using a real-world cohort of 141 patients in three high-volume medical centers in Milan , Tel Aviv and Antwerp . The researchers aimed to evaluate the efficacy of the Reducer in improving quality of life and reducing symptoms of angina pectoris in 141 consecutive patients suffering from coronary artery disease and chronic refractory angina.

  • PR Newswirelast month

    Neovasc to Present at the 38th Annual Canaccord Genuity Growth Conference

    NASDAQ, TSX: NVCN VANCOUVER , Aug. 6, 2018 /PRNewswire/ - Neovasc, Inc. ("Neovasc" or the "Company") (NASDAQ:NVCN) (TSX: NVCN), a leader in the development of minimally invasive transcatheter ...

  • CNW Grouplast month

    Neovasc to Present at the 38th Annual Canaccord Genuity Growth Conference

    Neovasc to Present at the 38th Annual Canaccord Genuity Growth Conference

  • CNW Group2 months ago

    Neovasc Announces Collaboration and Licensing Agreement with Penn Medicine and the Gorman Cardiovascular Research Group

    VANCOUVER , Aug. 3, 2018 /CNW/ - Neovasc Inc. ("Neovasc" or the "Company") (NVCN) (NVCN.TO), a leader in the development of minimally invasive transcatheter mitral valve replacement technologies, announced today that it has entered into a collaboration and licensing agreement relating to certain know-how developed by Penn Medicine and the Gorman Cardiovascular Research Group at the University of Pennsylvania (together, "Penn"). This Agreement resolves certain potential claims against the Company that were described in the Company's Annual Report on Form 20-F and management's discussion and analysis for Q1. This agreement does not impact either Penn or Neovasc's patent rights. Tiara™ ("Tiara") is Neovasc's minimally invasive transcatheter device for patients who experience severe mitral regurgitation ("MR").

  • PR Newswire2 months ago

    Neovasc Announces Collaboration and Licensing Agreement with Penn Medicine and the Gorman Cardiovascular Research Group

    VANCOUVER, Aug. 3, 2018 /PRNewswire/ - Neovasc Inc. ("Neovasc" or the "Company") (NVCN) (NVCN.TO), a leader in the development of minimally invasive transcatheter mitral valve replacement technologies, announced today that it has entered into a collaboration and licensing agreement relating to certain know-how developed by Penn Medicine and the Gorman Cardiovascular Research Group at the University of Pennsylvania (together, "Penn"). This Agreement resolves certain potential claims against the Company that were described in the Company's Annual Report on Form 20-F and management's discussion and analysis for Q1. This agreement does not impact either Penn or Neovasc's patent rights. Tiara™ ("Tiara") is Neovasc's minimally invasive transcatheter device for patients who experience severe mitral regurgitation ("MR").

  • CNW Group2 months ago

    Neovasc Announces Second Quarter 2018 Financial Results Conference Call and Webcast

    Neovasc Announces Second Quarter 2018 Financial Results Conference Call and Webcast